Indivior Pharmaceuticals (INDV) Stock Price
Indivior Pharmaceuticals Price
Revenue at Indivior Pharmaceuticals has contracted by 0.1% per year over the past 14 years to 1.24 B USD. Earnings per share have declined at 6.3% per year over the last 14 years. Indivior Pharmaceuticals's net margin stands at 16.9%, down from 25.9% several years earlier. Indivior Pharmaceuticals currently offers a dividend yield of about 1.40%. The payout ratio is around 227% of earnings. Analysts set a median price target of 48.00 USD, implying 83.5% above the current price. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.
Indivior Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Indivior Pharmaceuticals business model & stock analysis
Frequently asked questions about Indivior Pharmaceuticals
Analysts currently set an average price target of 48.00 USD for the Indivior Pharmaceuticals stock (median: 48.00 USD), implying +83.5 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Indivior Pharmaceuticals stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Indivior Pharmaceuticals to generate revenue of 1.33 B USD and earnings per share of 4.04 USD.
Converted at the current exchange rate, the Indivior Pharmaceuticals share trades at 23.54 EUR (26.16 USD).
The Indivior Pharmaceuticals share (INDV) is listed on 6 stock exchanges, including: London (INDV.L), SIX (Zürich) (2IV.SW), Frankfurt (2IV.F), München (2IV.MU), Düsseldorf (2IV.DU).
The expected revenue of Indivior Pharmaceuticals is 1.33 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Indivior Pharmaceuticals is 504.86 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Indivior Pharmaceuticals is currently 6.48. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Indivior Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Indivior Pharmaceuticals is currently 2.46. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Indivior Pharmaceuticals stock.
The Eulerpool Quality Score for Indivior Pharmaceuticals is 4/10.
The ISIN of Indivior Pharmaceuticals is US45579U1097. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Indivior Pharmaceuticals is A12FHW. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Indivior Pharmaceuticals is INDV. The ticker symbol is used to trade Indivior Pharmaceuticals shares on the stock exchange.
Indivior Pharmaceuticals stock
Indivior Pharmaceuticals Peer Group
Indivior Pharmaceuticals Ticker
All fundamentals and in-depth analysis of Indivior Pharmaceuticals
Our stock analysis for Indivior Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Indivior Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.